JPRN-UMIN000051941
Recruiting
未知
A Large-scale Longitudinal Cohort Study to MaintainWell-Being and Functioning in Middle and Elderly Adults - A Large-scale Longitudinal Cohort Study to MaintainWell-Being and Functioning in Middle and Elderly Adults
niversity of Tsukuba0 sites10,000 target enrollmentAugust 19, 2023
ConditionsHealthy subjects
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Healthy subjects
- Sponsor
- niversity of Tsukuba
- Enrollment
- 10000
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Persons who could not give consent to participate in this study 2\) Those who are unable to confirm their own will due to dementia or other reasons 3\) Persons who are judged by the principal investigator to be unsuitable to participate in this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)EUCTR2019-004294-13-GBGalderma S.A.400
Recruiting
Phase 3
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis.atopic dermatitischronic skin inflammation10014982NL-OMON54779Galderma15
Recruiting
Phase 3
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo NodularisNL-OMON54290Galderma10
Active, not recruiting
Phase 1
ong-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic DermatitisAtopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2019-001889-15-NLGalderma S.A.1,749
Active, not recruiting
Phase 1
ong-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic DermatitisEUCTR2019-001889-15-EEGalderma S.A.1,749